Summary

Servier, the French pharmaceutical company, has launched a €200 million venture fund—one of the largest new pharma‑backed VC vehicles in recent years—to accelerate investment into Europe’s biotech ecosystem. According to Alexis Vandier, head of the new fund, Europe offers strong scientific output, lower development costs, and a growing pool of deep‑pocketed later‑stage investors. However, the region continues to experience a critical funding gap at seed, Series A and Series B stages, where many founders struggle to raise sufficient capital to reach their next inflection points. The fund aims to support startups with high‑quality science in oncology, neurology, and adjacent therapeutic areas, helping them scale without being forced too early onto public markets. Recent billion‑dollar acquisitions of European biotechs—including Vicebio (UK), Araris Biotech (Switzerland) and EsoBiotec (Belgium)—demonstrate the continent’s growing potential for value creation.

Why This Matters for the Life Sciences Sector

Europe’s biotech sector has long been recognised for its outstanding research capabilities but has lagged behind the US in early‑stage funding density and the availability of experienced leadership teams. Servier’s new fund directly addresses this structural challenge. With later‑stage European VC funds now raising $1bn‑sized vehicles, the capital bottleneck has increasingly shifted earlier in the pipeline. Servier’s entry—alongside active corporate investors such as Angelini Ventures and Boehringer Ingelheim Venture Fund—signals a market moving toward more mature growth pathways, enabling biotechs to avoid premature public listings and build clinical‑ready organisations with sufficient capital, talent and scientific depth.

Expert Insight from Origio Partners

Talent & Leadership Implications

• Early‑stage biotech companies receiving larger Series A/B funding rounds require experienced scientific and operational leaders capable of transforming platform‑stage science into a scalable pipeline.
• As more corporate VCs invest heavily in strategic therapeutic areas (oncology, neurology), demand will grow for executives with deep clinical development expertise, regulatory know‑how, and partnership‑building experience.
• Companies looking to de‑risk translation ahead of large clinical inflection points must build teams with CMC, translational biology, and program leadership skills earlier than before.

What This Means for Hiring

• Startups supported by new funds like Servier Ventures will seek hybrid scientific‑commercial leaders who can drive both R&D strategy and investor engagement.
• To compete effectively for global capital, European biotechs need to recruit leadership talent with international experience, especially those familiar with US regulatory expectations and dealmaking norms.
• As corporate venture funds often provide access to scientific expertise, companies will prioritise leaders who can integrate external strategic input while maintaining agile, founder‑driven execution.

How Origio Partners Supports Organisations in This Space

Origio Partners works with emerging and scaling biotechs across Europe, the UK, and the US to build leadership teams capable of translating breakthrough science into compelling value inflection. We help founders and Boards recruit:

• Chief Scientific Officers and translational R&D leaders
• Clinical development and regulatory strategists
• Business development, partnering and corporate strategy leaders
• CEOs and COOs for early‑stage, venture‑backed biotech companies

Our retained search model ensures deep domain mapping and targeted leadership identification at the moments funding and scientific progress align.

Key Takeaways

• Servier has launched a €200m fund to back European biotech startups, one of the largest new pharma‑VC vehicles in recent years.
• Europe offers strong science and lower development costs than the US but continues to face Series A/B funding gaps.
• Increased participation from corporate VC arms is strengthening European late‑stage financing and reducing pressure to list prematurely.
• High‑profile European biotech acquisitions highlight the region’s potential for significant returns.
• Talent needs are shifting toward experienced scientific, clinical and BD leadership capable of scaling early‑stage companies.